# A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

> **NCT00069095** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 2035 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Oxaliplatin 130 mg/m^2
- **DRUG:** Capecitabine 1000 mg/m^2
- **DRUG:** Bevacizumab 7.5 mg/kg
- **DRUG:** Placebo for bevacizumab 7.5 mg/kg
- **DRUG:** Oxaliplatin 85 mg/m^2
- **DRUG:** Leucovorin 200 mg/m^2
- **DRUG:** Fluorouracil 400 mg/m^2
- **DRUG:** Bevacizumab 5 mg/kg
- **DRUG:** Placebo for bevacizumab 5 mg/kg

## Key facts

- **NCT ID:** NCT00069095
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2006-01
- **Final completion:** 2009-04
- **Target enrollment:** 2035 (ACTUAL)
- **Last updated:** 2016-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00069095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00069095, "A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00069095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*